Zenith Capital Corp. (ZHCLF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 1 | - | - | - |
| Operating profit | $m | -5 | - | ||||||
| Net profit | $m | -0 | -0 | -13 | -11 | -7 | - | - | - |
| EPS reported | $ | -0.05 | - | ||||||
| Operating cashflow per share | $ | 0.00 | - | ||||||
| Capex per share | $ | 0.00 | - | ||||||
| FCF per share | $ | 0.00 | - | ||||||
| Free cash flow | $m | 0 | - | ||||||
| Net debt | $m | 0 | - | ||||||
| Book value equity | $m | 0 | - | ||||||
| Book value per share | $ | 0.00 | - | ||||||
| Number of shares | m | 152.92 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.00 | - | ||||||
| P/S LTM | x | 69.69 | - | ||||||
| P/FCF LTM | x | 0.00 | - | ||||||
| EV/EBITDA LTM | x | -7.53 | - | ||||||
| EV/Sales LTM | x | 0.03 | - | ||||||
| Earnings Yield LTM | % | -480.59% | - | ||||||
| FCF Yield | % | 0.00% | - | ||||||
| Quality | |||||||||
| ROE | % | 0.00% | - | ||||||
| ROIC | % | 0.00% | - | ||||||
| Operating margin | % | -9.58% | - | ||||||
| Gross margin | % | +100.00% | - | ||||||
| FCF/Sales | % | 0.00% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.00 | - | ||||||
| EBIT/Net interest | x | -3.02 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | - | - | ||||||
| Gross debt/equity | x | - | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company's lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer Institute. The company was formerly known as Zenith Epigenetics Corp. and changed its name to Zenith Capital Corp. in August 2016. Zenith Capital Corp. was incorporated in 2013 and is headquartered in Calgary, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free